PHCbi Launches LiCellGrow™ System for Efficient Cell & Gene Therapy Production

PHC Corporation Biomedical Business Division introduces its innovative LiCellGrow™ platform to streamline scalable cell expansion, enhance process visibility, and support high-quality cell and gene therapy manufacturing. PHC Corporation Biomedical Business Division, a core subsidiary of PHC Holdings Corporation, has announced…

Read More PHCbi Launches LiCellGrow™ System for Efficient Cell & Gene Therapy Production
Tidewater

Tidewater Announces Financial Results for the Three and Twelve Months Ended December 31, 2025

Tidewater Reports Results for the Three and Twelve Months Ended December 31, 2025 Tidewater Inc. announced today revenue for the three and twelve months ended December 31, 2025 of $336.8 million and $1,352.8 million, respectively, compared with $345.1 million and…

Read More Tidewater Announces Financial Results for the Three and Twelve Months Ended December 31, 2025

Cure Rare Disease and LGMD2L Foundation Partner on Gene Therapy for Anoctamin 5 Disease

The collaboration funds a multi-year effort to advance a novel ANO5 gene replacement therapy from early development through clinical trial readiness for patients with LGMD2L. Cure Rare Disease (CRD), a nonprofit biotechnology organization dedicated to advancing treatments for rare and…

Read More Cure Rare Disease and LGMD2L Foundation Partner on Gene Therapy for Anoctamin 5 Disease